Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced the successful closing of its previously announced private placement of 823,045 shares of common stock at a purchase price of $1.215 per share, for aggregate gross proceeds of approximately $1.0 million, to Synt
July 17, 2020
· 2 min read